At a glance
- Originator Pfizer
- Class Antihyperlipidaemics
- Mechanism of Action LDL receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hypercholesterolaemia
Most Recent Events
- 10 Mar 2000 No-Development-Reported for Atherosclerosis in USA (Unknown route)
- 10 Mar 2000 No-Development-Reported for Hypercholesterolaemia in USA (Unknown route)
- 05 Jul 1995 Preclinical development for Hypercholesterolaemia in USA (Unknown route)